Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
(Click the title below to leave the MDLinx Network and go to the Journal's Website)
Statins and cancer risk
American Journal of Medicine, 03/28/08
Karp I et al. - Use of lipophilic statins at sufficiently high dose might be associated with a clinically important reduction in the incidence of cancer.
Methods- Objective was to investigate the relation between lipophilic statin use and cancer occurrence
- Pts (aged >=45 y) and survivors of acute myocardial infarction were included
- High- and low-dose statin use were defined as at or above (below) the statin-specific target dose, for any of the 4 lipophilic statin medications
- 30,076 pts, including high-dose, low dose, and non users were followed for up to 7 y
- Incidence rates of any type of cancer were 13.9, 17.2, and 26.0/1000 person-years in statin high-dose, low-dose, and non-users, respectively
- No significant time-dependence of the effect of statins at either dose was detected
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Valproic acid restores ERalpha and antiestrogen sensitivity to ERalpha-negative breast cancer cells
Molecular and Cellular Endocrinology, 11/25/09
N2 Disease in Patients With Head and Neck Squamous Cell Cancer Treated With Chemoradiotherapy
Archives of Otolaryngology, 11/25/09
Salvage treatment with upfront melphalan 100 mg/m2 and consolidation with novel drugs for fulminant progression of multiple myeloma
Annals of Hematology, 11/24/09
Sponsor
Article Search
Sponsor


See Latest Articles


